- Conditions
- Pancreatic Cancer
- Interventions
- Proton Radiation, Capecitabine, Surgical resection
- Radiation · Drug · Procedure
- Lead sponsor
- Proton Collaborative Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2040
- U.S. locations
- 4
- States / cities
- Little Rock, Arkansas • Jacksonville, Florida • Warrenville, Illinois + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 745–760
of 760
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
- Interventions
- CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
- Drug
- Lead sponsor
- Cyteir Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 16
- States / cities
- San Francisco, California • Stanford, California • Denver, Colorado + 12 more
- Conditions
- Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- Momelotinib (MMB), Capecitabine, Oxaliplatin
- Drug
- Lead sponsor
- Sierra Oncology LLC - a GSK company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Nashville, Tennessee + 1 more
- Conditions
- Rectal Cancer, Rectal Adenocarcinoma
- Interventions
- Lenvatinib, Capecitabine, External Radiation Therapy (XRT)
- Drug · Radiation
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
- Interventions
- tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more
- Conditions
- Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
- Interventions
- HLX22, Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine
- Drug
- Lead sponsor
- Shanghai Henlius Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 29
- States / cities
- Anaheim, California • Los Alamitos, California • Greeley, Colorado + 24 more
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Interventions
- exemestane, triptorelin pamoate, capecitabine, methotrexate, vinorelbine tartrate, paclitaxel, therapeutic conventional surgery, radiation therapy, laboratory biomarker analysis
- Drug · Procedure · Radiation + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Gastric Cancer
- Interventions
- Rilotumumab, Placebo, Epirubicin, Cisplatin, Capecitabine
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Aurora, Colorado • Pueblo, Colorado + 13 more
- Conditions
- Colorectal Cancer Metastatic, mCRC
- Interventions
- Aldoxorubicin Hydrochloride, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT
- Biological · Drug · Procedure
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- El Segundo, California
- Conditions
- Advanced Cancer, Pancreatic Cancer, Renal Cell Cancer, Non Small Cell Lung Cancer, Colorectal Carcinoma, Endometrial, Uterine
- Interventions
- Temsirolimus, Irinotecan, Irinotecan + capecitabine, nivolumab
- Drug
- Lead sponsor
- Western Regional Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Goodyear, Arizona
- Conditions
- Colorectal Cancer, Metastatic Cancer
- Interventions
- bevacizumab, capecitabine, oxaliplatin, conventional surgery
- Biological · Drug · Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 46
- States / cities
- Los Angeles, California • Aurora, Illinois • Joliet, Illinois + 25 more
- Conditions
- Colorectal Cancer
- Interventions
- Capecitabine and Cetuximab
- Drug
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Colorectal Cancer
- Interventions
- cetuximab, capecitabine, oxaliplatin, therapeutic surgical procedure, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 130
- States / cities
- Mobile, Alabama • Tucson, Arizona • Berkeley, California + 93 more
- Conditions
- Rectal Cancer, Colo-rectal Cancer
- Interventions
- Cetuximab, Oxaliplatin, Capecitabine, Radiotherapy, Diphenhydramine hydrochloride (HCl)
- Drug · Radiation
- Lead sponsor
- George Albert Fisher
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer
- Interventions
- Trastuzumab Deruxtecan, pembrolizumab, Trastuzumab, Chemotherapy
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 726 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 18
- States / cities
- New Haven, Connecticut • Skokie, Illinois • Kansas City, Kansas + 15 more
- Conditions
- Adenocarcinoma
- Interventions
- Bevacizumab, Capecitabine, Cisplatin, Placebo, 5-fluorouracil
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 774 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 13
- States / cities
- Beverly Hills, California • La Jolla, California • Los Angeles, California + 9 more